Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07429318

Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer

This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Sex eligibility

All sexes

Study type

Observational

Primary location

Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.)
  • (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI.
  • (3) Patients who underwent adjuvant therapy before surgery.
  • (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences.
  • (5) Patients who have complete clinical, pathological and imaging data.

Exclusion criteria

  • (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC).
  • (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery.
  • (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ.
  • (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery.
  • (5) Patients whose key diagnosis and treatment information records were missing.

Treatment and study plan

Chemo only

Procedure

Patients who only used chemotherapy during neodajuvant treatment period

Other names: chemothreapy

Immunochemotherapy

Procedure

Patients who used immunotherapy combined with chemotherapy during neodajuvant treatment period

Other names: immunotherapy combined with chemotherapy

Primary outcomes

  1. OS

    Time frame: From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months.

    overall survival

Secondary outcomes

  1. EFS

    Time frame: From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 100 months.

    event free survival

  2. DFS

    Time frame: From the start date of cycle 1 (each cycle is 14 days or 21 days) adjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

    disease free survival

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Official study title

Efficacy and Survival Prognosis Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Acronym: GC/GEJC

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 24, 2026
Registry last updated
Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.